Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care

European Journal of Health Economics

Volumn 7, Issue 1, 2006, Pages 72-78

  Edwards, Steven J ^a   Campbell, Helen E ^b   Plumb, Jonathan M ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cost utility analysis; Imipenem; Infection; Intensive care; Meropenem

Indexed keywords

ANTIBIOTIC AGENT; CILASTATIN PLUS IMIPENEM; MEROPENEM;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; INFECTION; INTENSIVE CARE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEPSIS; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; UNITED KINGDOM; URINARY TRACT INFECTION;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CILASTATIN; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIPEPTIDASES; DRUG COMBINATIONS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; THIENAMYCINS;

EID: 33644853083     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-005-0333-y     Document Type: Article

References (16)

1. Edwards SJ, Emmas CE, Campbell HE (2005) Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. Curr Med Res Opin 21:785-794
2. Wright JC, Plenderleith L, Ridley SA (2000) Long-term survival following intensive care: subgroup analysis and comparison with the general population. Anaesthesia 58:637-642
3. Garau J, Blanquer J, Cobo L, Corcia S, Daguerre M, de Latorre FJ, Leon C, Del Nogal F, Net A, Rello J (1997) Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 16:789-796
4. Rosenberg AL, Watts C (2000) Patients readmitted to ICUs: a systematic review of risk factors and outcomes. Chest 118:492-502
5. Anonymous (1999) National statistics. Mortality statistics: England and Wales 1999. TSO: London
6. Anonymous (2004) National statistics. Annual abstract of statistics 2004. TSO: London
7. Anonymous (2004) NHS reference costs 2003 and national tariff 2004. Payment by results. Core tools. Available at: http://www.dh.gov.uk/ PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/ PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_10=4070195&chk=UzhHA3
8. Anonymous (2003) British national formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain: London
9. Kerridge RK, Glasziou PP, Hillman KM (1995)The use of "quality-adjusted life years" (QALYs) to evaluate treatment in intensive care. Anaesth Intensive Care 23:322-331
10. National Institute for Clinical Excellence (2004) Technology appraisals process: guide to the methods of technology appraisal. Available at:http://www.nice.org.uk/page.aspx?o=201973
11. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 22:290-308
12. Rawlins MD, Culyer AJ (2004) National Institute for Clinical Excellence and its value judgments. BMJ 329:224-227
13. Smyth ETM, Barr JG, Hogg GM (1996) An assessment of hidden costs on total prescribing costs of courses of meropenem and imipenem/cilastatin. Br J Med Econ 10:325-340
14. Plumridge RJ (1997) Cost analysis of infusion versus injection delivery of imipenem/cilastatin and meropenem. Clin Drug Invest 14:132-136
15. Attanasio E, Russo P, Carunchio G, Basoli A, Caprino L (2000) Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections. Dig Surg 17:164-172
16. Basoli A, Meli EZ, Mazzocchi P, Speranza V (1997) Imipenem/cilastatin (1.5 mg daily) versus meropenem (3 g daily) in patients with intra-abdominal infections: results of a prospective, randomised, multicentre trial. Scand J Infect Dis 29:503-508